This video was recorded live on September 6, 2018 from an Independent Satellite Symposium preceding the 2018 ASH Meeting on Hematologic Malignancies.
Are there “right” and “wrong” choices when considering treatment options?
Hear updates from Dr. Parameswaran Hari and Dr. Saad Usmani on the treatment of relapsed/refractory multiple myeloma. These myeloma experts examine the science and research behind making the most appropriate therapeutic choices and demonstrate the art of navigating these complex clinical decisions.
Upon completion of this educational activity, participants should be able to:
- Compare and contrast therapeutic strategies for multiple myeloma patients experiencing relapse: first, second, third or beyond
- Evaluate factors that must be considered in selecting and sequencing treatments at first relapse and beyond
- Identify strategies for monitoring and proactively managing adverse events that a patient may experience while on active therapy
- Outline emerging therapeutic strategies that, upon approval, have the potential to impact treatment and patient outcomes
Supported by educational grants from Celgene Corporation and Sanofi Genzyme